**Daiichi Sankyo Modality Collaboration (application: Dec. 1 2021- Feb. 28 2022)**

Drug discovery research with DS-original nucleic acid therapeutics

- **[Modality]** DS-original chemically modified nucleic acid therapeutics. N-Acetylgalactosamine (GalNAc) conjugation is available for liver delivery.
- **[Roles]** Applicants will propose target gene(s) and conduct biological assays. DS will synthesize nucleic acid therapeutics.
- **[Research areas]** Non-oncology (rare disease, CNS, eyes, heart, autoimmune disease)
- **[Research stage]** lead discovery
- **[Budget]** $300,000 per year including overhead/indirect costs
- **[Term]** Two years

**Guidelines for Application**

Application is on email basis. For inquiry and an application form, please contact Masakatsu Suzuki, PhD (masuzuki@dsi.com).

Eligibility: Researchers affiliated with universities and research institutions in PA/NJ/MD regions, who are willing to develop drugs for intractable diseases. The program is not open to undergraduate or graduate students.

Research Budget: $300,000 per year (including overhead/indirect costs)

Term: Two years based on the successful achievement of the first year’s milestone. Successful program(s) will be considered for the further collaboration framework

**Selection Criteria:**

- Matching needs (Research Interests)
- Originality and uniqueness of research
- Possibility for drug generation program
- Feasibility of research plan
- Non-redundancy with Daiichi Sankyo’s internal research projects and current collaboration.

**Schedule:**

1. Application: December 1, 2021 to February 28, 2022
2. Notification of preliminary decisions: April 21, 2022
3. Inquiry for confidential information under CDA: April 28 to May 25
4. In-person or virtual interview: from early to mid June
5. Notification of final decision: early July

**Research Interests:**

I. Monogenic rare diseases
II. Psychiatric diseases
III. Neurodegenerative diseases caused by protein misfolding
IV. Diabetic macular edema
V. Chronic heart failure
VI. Autoimmune diseases

**Parallel Application to Other Grants**

**Public Grant**

DS accepts application that has already applied to public grants which meet following requirements. IPs obtained by public grants belong to PI and/or university.

**Pharma-Sponsored Grant**

DS accepts application that has already applied to other company’s private grants. DS reserves the right to decline application if application is accepted to another firm’s private grant prior to DS’s final decision.